Eckert & Ziegler: Strong Growth in Sales and Income
2019-08-13 / Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, achieved record sales of € 89.0 million in the first half of 2019. The sales increased by € 8.0 million or 10% when compared to the previous year. Earnings per share rose by 57% to € 2.55.
The fastest-growing segment was the Radiopharma segment, mainly driven by continuing strong sales of pharmaceutical radioisotopes to reach a level of € 21.7 million, representing an increase of € 6.3 million or 41%. The revenue generated by the Isotope Products segment also increased by 5% or € 4.2 million to € 54.2 million The Radiation Therapy segment, however, recorded a slight drop in sales, achieving € 13.2 million, which represents a fall of around 8% year-on-year.
The operating cash flow rose significantly by € 9.1 million to € 14.2 million. Decisive factors here were the increase of € 4.5 million in the result for the period and non-cash effects from depreciation and amortization, which rose by € 1.5 million. In total, cash and cash equivalents increased by € 2.9 to
€ 57.1 million as at June 30, 2019 as compared with the end of 2018.
For the fiscal year 2019 the management expects sales revenues of around € 180 million and earnings of around € 4.00 per share. This outlook continues to be based on the assumption that the Euro exchange rate does not exceed USD 1.20.
The complete financial statements can be viewed here.
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.